Month: March 2013

Systems and Structural Biology Center at RIKEN Yokohama will reinforce studies on proteins containing unnatural amino acids

Based on the extensive tools in molecular genetics and instruments available at RIKEN Yokohama and on long-standing experience with the incorporation of unnatural amino acids in proteins such as antibodies, RIKEN will employ several teams headed by senior researchers to this field and make it a focus at its newly founded Center for Life Science […]

Team at University of Tokyo solves structure of multidrug exporter of Pyrococcus furiosus, relevant for fighting antibiotic resistance

The team of Professor Osamu NUREKI at the University of Tokyo crystallized a “multidrug and toxic compound extrusion exporter” protein (MATE) within a lipid and solved its x-ray structure. The membrane protein is v-shaped and in the presence of a drug changes conformation to a bent shape, thus pushing a drug out of the cell. […]

Dainippon Sumitomo Pharma buys all open stock of Retina Institute Japan K.K., an iPS company

Retina Institute Japan, Fukuoka, develops an iPS-based cure for age-related macular degeneration. The IP is on exclusive license from RIKEN, and Dainippon Sumitomo Pharma buys for 1.500 million Yen (12 million €) on an exclusive third party agreement. Retina Institute Japan was founded only in February, 2011. Dainippon Sumitomo Pharma press release, March 28, 2013

RITE and Sumitomo Rubber establish a C. glutamicum pathway from biomass to anilin

In collaboration with Sumitomo Rubber Industries, RITE researchers have used their principal host organism, C. glutamicum, which can be grown in a high-cell density resting mode, to engineer a new pathway leading to anilin. Anthranilic acid decarboxylase was sreened from Enterobacter cloacae and ctivity enhanced 2,5 fold by a combination of directed evolution and rational […]

Scroll to top